Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GMNN | O75496 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29572125 | 1.00 | MAPT (0.40) | MAPTALDH1A1POLBMAPK1KDM4E | |
| SCHEMBL15271092 | 0.83 | ALDH1A1 (0.36) | MAPTALDH1A1POLBMAPK1KDM4E | |
| SCHEMBL30745103 | 0.83 | CYP4F2 (0.40) | MAPTALDH1A1POLBMAPK1KDM4E | |
| SCHEMBL289465 | 0.83 | CYP4F2 (0.40) | MAPTALDH1A1POLBMAPK1KDM4E | |
| SCHEMBL17131112 | 0.82 | ALDH1A1 (0.38) | MAPTALDH1A1POLBMAPK1KDM4E | |
| SCHEMBL30402328 | 0.81 | ALDH1A1 (0.40) | MAPTALDH1A1POLBMAPK1KDM4E | |
| SCHEMBL17544367 | 0.81 | ALDH1A1 (0.40) | MAPTALDH1A1POLBMAPK1KDM4E | |
| SCHEMBL30849372 | 0.81 | KDM4E (0.40) | MAPTALDH1A1POLBMAPK1KDM4E | |
| SCHEMBL31006673 | 0.79 | PTPN1 (0.49) | MAPTALDH1A1POLBMAPK1KDM4E | |
| SCHEMBL16634805 | 0.79 | PTPN1 (0.49) | MAPTALDH1A1POLBMAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3596059-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS DUAL ATX/CA INHIBITORS | HOFFMANN LA ROCHE (CH) | 2024-04-24 | — | — | EP | disclosed |
| CN-110392679-B | Heterocyclic compounds useful as dual ATX/CA inhibitors | 豪夫迈·罗氏有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-107922415-B | Novel bicyclic compounds as dual ATX/CA inhibitors | 豪夫迈·罗氏有限公司 | 2022-04-15 | — | — | CN | disclosed |
| EP-3353178-B1 | BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-07-14 | — | — | EP | disclosed |
| US-11059794-B2 | Heterocyclic compounds useful as dual ATX/CA inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20200223854-A1 | BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-07-16 | — | — | US | disclosed |
| US-10647719-B2 | Bicyclic compounds as dual ATX/CA inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20180215765-A1 | NEW BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2018-08-02 | — | — | US | disclosed |
| EP-3353178-A1 | NEW BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2018-08-01 | — | — | EP | disclosed |
| WO-2017050791-A1 | NEW BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200223854-A1 | BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | ATXN2, ATXN2L, ATXN10 | MAPT 2303/4885ALDH1A1 4285/4885POLB 1857/4885 |
| US-20180215765-A1 | NEW BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | ATXN2, ATXN2L, ATXN10 | MAPT 2418/4885ALDH1A1 4352/4885POLB 1847/4885 |
| US-10647719-B2 | Bicyclic compounds as dual ATX/CA inhibitors | ATXN2, ATXN2L, ATXN10 | MAPT 2303/4885ALDH1A1 4285/4885POLB 1857/4885 |
| US-11059794-B2 | Heterocyclic compounds useful as dual ATX/CA inhibitors | ATXN2, ATXN2L, ATXN10 | MAPT 2979/4885ALDH1A1 3727/4885POLB 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.